• 1
    Gora-Tybor, J., Emerging therapies in chronic myeloid leukemia. Curr. Cancer Drug Targets. 2012, 12, 458470.
  • 2
    Ernst, T., Hochhaus, A., Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin. Oncol. 2012, 39, 5866.
  • 3
    Mahon, F. X., Belloc, F., Lagarde, V., Chollet, C. et al., MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101, 23682373.
  • 4
    Lee, F., Fandi, A., Voi, M., Overcoming kinase resistance in chronic myeloid leukemia. Int. J. Biochem. Cell. Biol. 2008, 40, 334343.
  • 5
    Quintás-Cardama, A., Kantarjian, H. M., Cortes, J. E., Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16, 122131.
  • 6
    Colavita, I., Esposito, N., Martinelli, R., Catanzano, F. et al., Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. Biochim. Biophys. Acta 2010, 1804, 19741987.
  • 7
    Esposito, N., Colavita, I., Quintarelli, C., Sica, A. R. et al., SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 2011, 118, 36343644.
  • 8
    Balabanov, S., Gontarewicz, A., Ziegler, P., Hartmann, U. et al., Hypusination of eukaryotic initiation factor 5A(eIF5A): a novel therapeutic target in BCR-ABL–positive leukemias identified by a proteomics approach. Blood 2007, 109, 17011711.
  • 9
    Mahon, F. X., Deininger, M. V. N., Schultheis, B., Chabrol, J. et al., Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96, 10701079.
  • 10
    Gerke, V., Moss, S. E., Annexins: from structure to function. Physiol. Rev. 2002, 82, 331337.
  • 11
    Gerke, V., Creutz, C. E., Moss, S. E., Annexins: linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell. Biol. 2005, 6, 449461.
  • 12
    Debret, R., Btaouri, H. E., Duca, L., Rahman, I. et al., Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells. FEBS Lett. 2003, 546, 195202.
  • 13
    Solito, E., De Coupade, C., Canaider, S., Goulding, N. J., Perretti, M., Transfection of annexin 1 in monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with caspase-3 activation. Br. J. Pharmacol. 2001, 133, 217228.
  • 14
    Solito, E., Kamal, A., Russo-Marie, F., Buckingham, J. C. et al., A novel calcium dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J. 2003, 17, 15441546.
  • 15
    Perretti, M., D'Acquisto, F., Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 2009, 9, 6270.
  • 16
    Cheng, T. Y., Wu, M. S., Lin, J. T., Lin, M. T. et al., Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway.Cancer 2012, doi:10.1002/cncr.27565.
  • 17
    Wang, Y., Serfass, L., Roy, M. O., Wong, J. et al., Annexin-I expression modulates drug resistance in tumor cells. Biochem. Biophys. Res. Commun. 2004, 314, 565570.
  • 18
    Chow, B. H., Chua, D. T., Sham, J. S., Zhang, M. Y. et al., Increased expression of annexin I is associated with drug-resistance in nasopharyngeal carcinoma and other solid tumors. Proteomics Clin. Appl. 2009, 3, 65462.
  • 19
    Zhu, F., Wang, Y., Zeng, S., Fu, X. et al., Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. OMICS 2009, 13, 467476.
  • 20
    Wang, N., Li, Z., Ding, R., Frank, G. D. et al., Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signalling. J. Biol. Chem. 2006, 281, 2187821883.
  • 21
    Hatfield, M. P., Lovas, S., Role of Hsp70 in cancer growth and survival. Protein Pept. Lett. 2012, 19, 616624.
  • 22
    Kim, J. E., Chen, J., Lou, Z., p30 DBC is a potential regulator of tumorigenesis. Cell Cycle 2009, 8, 29322935.
  • 23
    Vizcaíno, J. A., Côté, R. G., Csordas, A., Dianes, J. A., et al., The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2012, doi: 10.1093/nar/gks1262.